Companies · Other

EMMAC Life Sciences Ltd

LONDON · Other

Diligence memoA one-page analyst read on EMMAC Life Sciences Ltd — recommendation, valuation, rhythm, risks.
$28.4M
Total raised · real
5
Rounds
0.0×
Latest step-up
Top 12%
Sector rank · raised
Series A
Latest stage · inferred · Mon Feb 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

EMMAC Life Sciences Ltd looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.04× the median modeled value of Series A Other companies in 2019–2021 (858 peers) — value vs value, same stage and era.
Dormant
  • Last raise 5.4 yr ago; this sector typically re-raises about every 11 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other

EMMAC Life Sciences Ltd is one of 25015 Other companies tracked from LONDON. By capital raised it ranks in the upper tier (ahead of 89% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
3
Investors (latest)
2018
Year incorporated
2021-02-22
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2018-09-20 Raised $911K (real) Modeled valuation $21M (est)$911K$21MPre-Seed2018Series A · 2018-12-20 Raised $5.3M (real) Modeled valuation $81M (est)$5.3M$81MSeries A2018Series A · 2019-07-04 Raised $13M (real) Modeled valuation $189M (est)$13M$189MSeries A2019Series A · 2020-11-26 Raised $9.4M (real) Modeled valuation $126M (est)$9.4M$126MSeries A2020Series A · 2021-02-22 Raised $251K (real) Modeled valuation $3.1M (est)$251K$3.1MSeries A2021+$5.3M+$13M+$9.4M+$251KCumulative $28M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$911K · 2018
Series A$5.3M · 2018no Seed on file
Series A extension$12.5M · 2019
Series A extension$9.4M · 2020
Series A extension$251K · 2021

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$3.1M
Base estimate est.
$342K
Conservative case
$14.7M
Upside case
$1.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Pre-Seed · modeled $21.1M · 2018-09-202018Series A · modeled $80.6M · 2018-12-20Series A · modeled $189.5M · 2019-07-04Series A · modeled $126.4M · 2020-11-26Series A · modeled $3.1M · 2021-02-222021
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
55%
Survival probability
30% low · 75% high
1.35×/yr
Annual markup
1.70×/yr upside case
5.4 yr
Elapsed time used
5.4 yr actual, capped for stale marks
general
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
7 mo
Avg between rounds
$11.7M/yr
Capital velocity
7.8 yr
On record since
2018
First round
5
Rounds on file
How it compares to the market

Benchmarked against 25015 companies in Other. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 14× above median
This company$28.4M
Sector median$2.0M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.0× of median
This company$251K
Sector median$5.7M
Modeled value — vs sector median (estimate, all stages) 0.2× of median
This company$3.1M
Sector median$17.7M

Raised more than 89% of sector peers (real $). Modeled value above 18% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #846 of 858.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)No More Landfills Investment Group, LLC · Series A Raised $15.0M · modeled $227.0M (est)3901 Campbellton Rd., LLC · Series A Raised $15.0M · modeled $227.0M (est)medpai group · Series A Raised $15.0M · modeled $227.0M (est)WestCap Bolt, LLC · Series A Raised $15.0M · modeled $227.0M (est)HBC Management Class B L.P. · Series A Raised $15.0M · modeled $226.3M (est)Globus Maritime Ltd · Series A Raised $27.4M · modeled $223.4M (est)Redwood Holding Group, LLC · Series A Raised $21.1M · modeled $222.5M (est)Sol de Janeiro Holdings, Inc. · Series A Raised $14.6M · modeled $220.6M (est)Patrick Partners LLC · Series A Raised $14.5M · modeled $219.4M (est)Concord Resources Holdings Ltd · Series A Raised $14.4M · modeled $218.2M (est)Bigstream Solutions, Inc. · Series A Raised $19.8M · modeled $216.3M (est)Engageli, Inc. · Series A Raised $14.5M · modeled $215.8M (est)EMMAC Life Sciences Ltd (this company) Raised $28.4M · modeled $3.1M (est)EMMAC Life Sciences Ltd
CompanyStageRaised · realValue · estvs peer med.
No More Landfills Investment Group, LLCSeries A$15.0M$227.0M2.81×
3901 Campbellton Rd., LLCSeries A$15.0M$227.0M2.81×
medpai groupSeries A$15.0M$227.0M2.81×
WestCap Bolt, LLCSeries A$15.0M$227.0M2.81×
HBC Management Class B L.P.Series A$15.0M$226.3M2.80×
Globus Maritime LtdSeries A$27.4M$223.4M2.76×
Redwood Holding Group, LLCSeries A$21.1M$222.5M2.75×
Sol de Janeiro Holdings, Inc.Series A$14.6M$220.6M2.73×
Patrick Partners LLCSeries A$14.5M$219.4M2.71×
Concord Resources Holdings LtdSeries A$14.4M$218.2M2.70×
Bigstream Solutions, Inc.Series A$19.8M$216.3M2.67×
Engageli, Inc.Series A$14.5M$215.8M2.67×
EMMAC Life Sciences Ltd this companySeries A$28.4M$3.1M0.04×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$911K2018-09-20$5.1M$21.1M90%
Series A$5.3M2018-12-20$24.2M$80.6M90%
Series A$12.5M2019-07-04$56.9M$189.5M90%
Series A$9.4M2020-11-26$42.8M$126.4M90%
Series A$251K2021-02-22$1.1M$3.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$911K2018-09-20
    • First recorded raise — entered as Pre-Seed.
    • 10 investors on this round.
  2. Series A$5.3M2018-12-20
    • Came back fast: 3 mo vs the ~11 mo sector norm.
    • Round 5.8× larger than the prior — scaling up.
    • 8 investors on this round.
  3. Series A$12.5M2019-07-04
    • Came back fast: 6 mo vs the ~11 mo sector norm.
    • Round 2.3× larger than the prior — scaling up.
    • 8 investors on this round.
  4. Series A$9.4M2020-11-26
    • Raised 17 mo later, in step with the ~11 mo sector norm.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 10 investors on this round.
  5. Series A$251K2021-02-22
    • Came back fast: 3 mo vs the ~11 mo sector norm.
    • Round 37.6× smaller than the prior — bridge or down round.
    • 3 investors on this round.
Intelligence
2021 ~Q4
Modeled next raise · ~7mo cadence
$251K
Modeled next size est.range $251K$401K
0.0×
Last step-up
$11.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Lorne Abony2 other2018-09
Antonio Costanzo1 other2018-09
Barbara Pacchetti2018-09
Edward McDermott2018-09
Orr Yarkoni2018-09
Thomas Ellen2018-09
Thomas Rooke2018-09
Registry & provenance

EMMAC Life Sciences Ltd is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1789520
SEC CIK
2018
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Yooma Wellness Inc.HealthtechSeries A$17.7M$19.2Mnetwork2 shared operators · same stage
Sadot Group Inc.OtherSeries A$29.8M$3.1Msame sector · same stage
Avalon Advanced Materials Inc.OtherSeries A$30.0M$3.1Msame sector · same stage
Ireland Inc.OtherSeries A$22.4M$3.0Msame sector · same stage
teaRIOT, LLCOtherSeries A$16.8M$3.3Msame sector · same stage
ADB Holdings Group, LPOtherSeries A$14.3M$3.0Msame sector · same stage
Resource Holdings, Inc.OtherSeries A$13.2M$3.1Msame sector · same stage
DriverReach Inc.OtherSeries A$12.1M$3.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Emmaus Life Sciences, Inc.PharmaceuticalsSeries B$2.9M84%
Awakn Life Sciences Inc.OtherSeed$21.5M83%
Awakn Life Sciences Corp.OtherSeed$3.6M82%
Terra Life Sciences Inc.OtherSeed$28.4M80%
Ault Life Sciences, Inc.OtherSeries C$1.7B80%
Bioharvest Sciences Inc.OtherSeries A$1.3M78%
Aquacultural Research CorpOtherSeed$6.2M78%
Life Science Prime, Inc.OtherPre-Seed$2.9M78%
Frequently asked
How much funding has EMMAC Life Sciences Ltd raised?
EMMAC Life Sciences Ltd has raised approximately $28.4M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is EMMAC Life Sciences Ltd's estimated valuation?
Provath's modeled valuation for EMMAC Life Sciences Ltd is approximately $3.1M (modeled range $342K–$14.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is EMMAC Life Sciences Ltd at?
EMMAC Life Sciences Ltd's latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Feb 22.
What does EMMAC Life Sciences Ltd do and where is it based?
EMMAC Life Sciences Ltd operates in the Other sector, based in LONDON.
Explore related

See where EMMAC Life Sciences Ltd sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at EMMAC Life Sciences Ltd, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.